Clinical trial
A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab (REGN2810) in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery
NCT06980038 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab (REGN2810) in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- May 27, 2026
- Completion date
- November 24, 2027
- Enrollment
- 44 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck squamous cell carcinoma, hypopharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, nasal cavity squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharyngeal squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent nasal cavity squamous cell carcinoma, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, stage iii laryngeal cancer ajcc v8, stage iii lip and oral cavity cancer ajcc v8, stage iii nasopharyngeal carcinoma ajcc v8, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8, stage iva laryngeal cancer ajcc v8, stage iva lip and oral cavity cancer ajcc v8, stage iva nasopharyngeal carcinoma ajcc v8, stage ivb laryngeal cancer ajcc v8, stage ivb lip and oral cavity cancer ajcc v8